Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) – Investment analysts at SunTrust Banks increased their Q2 2019 earnings per share estimates for Entasis Therapeutics in a research note issued on Monday, May 20th. SunTrust Banks analyst E. Nash now anticipates that the company will post earnings per share of ($1.06) for the quarter, up from their previous estimate of ($1.27). SunTrust Banks also issued estimates for Entasis Therapeutics’ Q3 2019 earnings at ($1.15) EPS, Q4 2019 earnings at ($1.30) EPS and FY2019 earnings at ($4.50) EPS.
Entasis Therapeutics (NASDAQ:ETTX) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.24).
Shares of ETTX stock opened at $6.25 on Wednesday. The company has a current ratio of 8.79, a quick ratio of 8.79 and a debt-to-equity ratio of 0.02. Entasis Therapeutics has a 1 year low of $3.97 and a 1 year high of $13.70. The firm has a market capitalization of $82.06 million and a price-to-earnings ratio of -0.51.
A number of hedge funds have recently modified their holdings of the business. FNY Investment Advisers LLC increased its stake in shares of Entasis Therapeutics by 13,801.0% during the 4th quarter. FNY Investment Advisers LLC now owns 13,901 shares of the company’s stock worth $56,000 after purchasing an additional 13,801 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Entasis Therapeutics during the 4th quarter worth about $56,000. Finally, Janney Montgomery Scott LLC acquired a new position in shares of Entasis Therapeutics during the 4th quarter worth about $169,000. Hedge funds and other institutional investors own 65.35% of the company’s stock.
Entasis Therapeutics Company Profile
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Featured Story: What impact do institutional investors have on markets?
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.